

CLAIMS*species**OC  
COX-2  
inhibitor*

*45* 1. Polymorphic B Form of 3-(cyclopropylmethoxy)-4-[4-(methylsulfonyl)phenyl]-5,5-dimethyl-5H-furan-2-one characterized by the powder x-ray diffraction pattern represented in figure 2.

10

*46* 2. A pharmaceutical composition comprising an amount which is effective for treating a COX-2 mediated disease of the Polymorphic B Form of 3-(cyclopropylmethoxy)-4-[4-(methylsulfonyl)phenyl]-5,5-dimethyl-5H-furan-2-one, according to claim 1 together with a pharmaceutically acceptable base and an inert carrier material.

15

*47* 3. The pharmaceutical composition according to claim 2, wherein the effective amount is 5 to 1 000 mg per day preferably 5 to 250 mg per day.

20

*48* 4. A process for preparing Polymorphic B Form 3-(cyclopropylmethoxy)-4-[4-(methylsulfonyl)phenyl]-5,5-dimethyl-5H-furan-2-one which comprises agitating Polymorphic A Form of 3-(cyclopropylmethoxy)-4-[4-(methylsulfonyl)phenyl]-5,5-dimethyl-5H-furan-2-one according to claim 1 with or without the presence of Polymorphic B seed in any solvent which shows a solubility for 3-(cyclopropylmethoxy)-4-[4-(methylsulfonyl)phenyl]-5,5-dimethyl-5H-furan-2-one and which does not react chemically with or bind to 3-(cyclopropylmethoxy)-4-[4-(methylsulfonyl)phenyl]-5,5-dimethyl-5H-furan-2-one.

25

*49* 5. The process for preparing Polymorphic B Form of 3-(cyclopropylmethoxy)-4-[4-(methylsulfonyl)phenyl]-5,5-dimethyl-5H-furan-2-one according to claim 4, wherein the solvent is selected from the group consisting of methanol, methyl tertio butyl ether, dimethylformamide or is selected from the group consisting of miscible combinations of dimethylformamide, methyl tertio butyl ether, and methanol.

*50* 6. The process for preparing Polymorphic B Form 3-(cyclopropylmethoxy)-4-[4-(methylsulfonyl)phenyl]-5,5-dimethyl-5H-furan-2-one according to claim 5, wherein the solvent is methanol.

*S1* 7. The process of any one of claims 4 to 6, wherein the Polymorph B seed is present in an amount of from about 0.5 to 1 percent by weight Polymorph A present.

*S2* 8. Polymorphic B form according to claim 1, whenever prepared by  
5 the process according to any one of claims 4 to 7 or by an obvious chemical equivalent thereof.

*S3* 9. Polymorphic B form according to claim 1 for use in the treatment of a COX-2 mediated disease.

*S4* 10. The use of a compound according to claim 1 for the treatment  
10 of a COX-2 mediated disease, or for the production of corresponding medicaments.

*S5* 11. A method for treating a COX-2 mediated disease which comprises administering to a host requiring such treatment an effective amount of Polymorphic B Form of 3-(cyclopropylmethoxy)-4-[4-(methylsulfonyl)phenyl]-  
15 5,5-dimethyl-5H-furan-2-one as defined in claim 1.

*Add B1*